Načítá se...
Pharmacokinetics of Alemtuzumab in Pediatric Patients Undergoing ex vivo T-Cell Depleted Haploidentical Hematopoietic Cell Transplantation
PURPOSE: Alemtuzumab is a humanized monoclonal antibody against CD52 which is predominantly present on T- and B-lymphocytes. Alemtuzumab has been used as part of conditioning regimens for prophylaxis against rejection and GVHD. While the mechanism of action is well-understood, the pharmacokinetics o...
Uloženo v:
| Vydáno v: | Cancer Chemother Pharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7735192/ https://ncbi.nlm.nih.gov/pubmed/33037919 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04160-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|